Michael Pratts
Psychiatry · Syracuse, NYNPI 1427382670
Payments from drug & device makers
Across 138 payments — averaging $287.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$16K
- AbbVie$12K
- Sunovion Pharmaceuticals Inc.$11K
- Teva Pharmaceuticals USA, Inc.$158
- E.r. Squibb & Sons, L.L.C.$117
- Indivior Inc.$98
- plus $522 from 12 others
What the payments were for
- Speaking & faculty fees$33,92885%
- Travel & lodging$3,4919%
- Food & beverage$2,1265%
- Education$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $15,596 |
| AbbVie(2 entities) | 30 | $12,152 |
| Sunovion Pharmaceuticals Inc. | 23 | $11,061 |
| Teva Pharmaceuticals USA, Inc. | 3 | $158 |
| E.r. Squibb & Sons, L.L.C. | 4 | $117 |
| Indivior Inc. | 7 | $98 |
| Lundbeck LLC | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Shire North American Group Inc | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 3 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $24 |
| Neuronetics, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$15,060
- INVEGA TRINZA$13,700
- VRAYLAR$11,843
- LATUDA$10,712
How this compares
$39,703 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 11 | $5,106 |
| Clozapine | 57 | $1,859 |
| Bupropion XlBupropion Hcl | 14 | $1,678 |
| Clonazepam | 44 | $892 |
| Aripiprazole | 13 | $818 |
| Sertraline Hcl | 12 | $253 |
| Alprazolam | 13 | $91 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $90 |
| Gabapentin | 12 | $83 |
| Duloxetine Hcl | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $77 | $5,10611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Syracuse
- Ahmed NizarSyracuse$763K
- Steven NaprawaSyracuse$561K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.